PPhantomAI

Mr. T.A

PID-20141

58 yrs · Male · 84 kg · 172 cm · Medical Ward A

Diagnosis
Type 2 diabetes mellitus, Chronic Kidney Disease Stage 3b
Vitals
BP142/88 mmHgHighBlood PressureReference90–120 / 60–80 mmHgActual142/88 mmHg
HR80 bpmNormalHeart RateReference60–100 bpmActual80 bpm
RR15/minNormalRespiratory RateReference12–20 breaths/minActual15/min
TEMP36.7°CNormalTemperatureReference36.1–37.2°CActual36.7°C
SPO298%NormalOxygen SaturationReference≥ 95%Actual98%
Labs
Serum Creatinine2.1 mg/dLHighSerum CreatinineReference0.5–1.3 mg/dLActual2.1 mg/dL
Creatinine Clearance27 mL/minSevereCreatinine ClearanceReference≥ 50 mL/min (normal/mild impairment)Actual27 mL/min
eGFR28 mL/min/1.73m²SevereeGFRReference≥ 60 mL/min/1.73m²Actual28 mL/min/1.73m²
Liver FunctionWithin normal limitsNormalLiver FunctionReferenceWithin normal limitsActualWithin normal limits
Blood Glucose9.8 mmol/L (random)ElevatedBlood GlucoseReference4.0–7.8 mmol/LActual9.8 mmol/L (random)
HbA1c8.4%HighHbA1cReference< 5.7% normal · ≥ 6.5% diabetic rangeActual8.4%
Allergies & Status
No known drug allergies (NKDA)
Not applicable
Clinical Notes
Referred from outpatient diabetes clinic for glycaemic control. Metformin initiated at standard adult dose without renal function being cross-checked against the most recent labs.

Current Medications

  • Atorvastatin 20 mg once daily
  • Gliclazide 80 mg once daily

New Prescriptions — Pending Dispense

Metformin 1000 mg
Oral, Twice daily
Unit: 2600 Central: 5100 Reorder Not Needed
Glucometer Test Strips Box of 50Consumable
For home monitoring
Clinical AI Analysis
0%Risk Score
0%AI Confidence
HighPriority Level

Medication Interactions

Metformin + eGFR 28 mL/min/1.73m²Major

Metformin is renally cleared. At eGFR below 30, accumulation significantly raises the risk of lactic acidosis — a rare but life-threatening adverse effect carrying an FDA black box warning.

→ Metformin is generally not recommended at eGFR < 30. If initiated at all, this should only occur with specialist input; the prescribed dose (1000 mg BD) is inappropriate for this renal function.

Alternatives for Metformin
Linagliptin 5mg — Oral, Once daily
No renal dose adjustment needed; avoids metformin's lactic acidosis risk in renal impairment.

Alternatives

DPP-4 inhibitor (e.g., linagliptin, no renal dose adjustment needed) added to existing gliclazide
SGLT2 inhibitor — caution advised below eGFR 30 depending on specific agent; specialist input recommended

Counselling Points

This particular medication may not be suitable given current kidney function
Report unusual muscle pain, breathlessness, or severe stomach discomfort immediately
Kidney function will need to be rechecked regularly regardless of which medicine is chosen
Do Not Dispense

eGFR of 28 mL/min/1.73m² falls below the threshold at which metformin carries a black-box lactic acidosis risk. This prescription should be returned to the prescriber for a renally-appropriate alternative before any dispensing occurs.

Duplicate Prescription Check

No duplicate or overlapping therapy detected.

Dose Accuracy Check

Metformin 1000 mg — Within the typical adult range of 500-1000mg per dose.

Interaction Cross-Check

Every unique pair across current medications and new prescriptions — not just new-vs-current.

Atorvastatin + GliclazideLow
Atorvastatin + MetforminNew RxLow
Gliclazide + MetforminNew RxLow

Renal Function & Dosing

27SevereCreatinine ClearanceReference≥ 50 mL/min (normal/mild impairment)Actual27mL/min
Cockcroft-Gault recalculation: 45.6 mL/min
Severe Impairment
Metformin: Contraindicated below CrCl 30 — black box lactic acidosis risk

Pharmacovigilance — Relevant to This Patient

Metformin — GI upset14 hours ago

Acid-Base Disturbance Profile

Low
pH
7.32LowpHReference7.35–7.45Actual7.32
pCO₂
34 mmHgLowpCO₂Reference35–45 mmHgActual34 mmHg
HCO₃⁻
17 mEq/LLowHCO₃⁻Reference22–26 mEq/LActual17 mEq/L
Lactate
1.4 mmol/LNormalLactateReference< 2 mmol/LActual1.4 mmol/L
Metabolic AcidosisPartially Compensated (respiratory compensation in progress)

Low bicarbonate is driving the acidemia; a low pCO2 alongside it would indicate the lungs are already compensating by blowing off CO2.

→ Reflects his underlying CKD — a degree of chronic metabolic acidosis is expected at this level of renal impairment.

How This Affects the Treatment Plan — Suggested Interventions

Metabolic acidosis compounds metformin's lactic acidosis risk on top of any renal impairment — reinforces holding or avoiding metformin here.
Identify and treat the underlying cause (renal failure, DKA, lactic acidosis, toxin ingestion) rather than treating the pH number in isolation.
Recheck the metabolic panel and repeat the blood gas after any intervention to confirm the trend is genuinely improving.

Theatre

No theatre procedure currently scheduled for this patient.

Unit vs Central Stock — This Patient's Medications

AMC, ROL, and months-of-stock (MOS) at both the unit and central store, with a recommendation for each.

Atorvastatin
Unit StockAdequate
780
Stock
400
AMC
2
MOS

Stock within normal range (~2 months of stock) — no action needed.

Central StoreAdequate
3800
Stock
2400
AMC
1.6
MOS

Stock within normal range (~1.6 months of stock) — no action needed.

Gliclazide
Unit StockAdequate
340
Stock
245
AMC
1.4
MOS

Stock within normal range (~1.4 months of stock) — no action needed.

Central StoreAdequate
1500
Stock
1450
AMC
1
MOS

Stock within normal range (~1 months of stock) — no action needed.

Metformin
Unit StockAdequate
2600
Stock
860
AMC
3
MOS

Stock within normal range (~3 months of stock) — no action needed.

Central StoreAdequate
5100
Stock
4200
AMC
1.2
MOS

Stock within normal range (~1.2 months of stock) — no action needed.